WO2014122537A3 - Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin - Google Patents
Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin Download PDFInfo
- Publication number
- WO2014122537A3 WO2014122537A3 PCT/IB2014/000760 IB2014000760W WO2014122537A3 WO 2014122537 A3 WO2014122537 A3 WO 2014122537A3 IB 2014000760 W IB2014000760 W IB 2014000760W WO 2014122537 A3 WO2014122537 A3 WO 2014122537A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxychloroquine
- methods
- ribavirin
- combination
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Unit dosage form compositions and methods for preventing hepatitis C virus (HCV) replication in an HCV-infected subject are described herein, The compositions disclosed herein comprise amounts of hydroxychloroquine, or a pharmaceutically acceptable salt thereof, and ribavirin sufficient to prevent HCV replication. The methods of treatment disclosed herein comprise co-administering to the subject in need thereof therapeutically effective amounts of hydroxychloroquine and an antiviral agent for preventing HCV replication.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361760834P | 2013-02-05 | 2013-02-05 | |
US61/760,834 | 2013-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014122537A2 WO2014122537A2 (en) | 2014-08-14 |
WO2014122537A3 true WO2014122537A3 (en) | 2014-11-06 |
Family
ID=51014568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/000760 WO2014122537A2 (en) | 2013-02-05 | 2014-02-04 | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014122537A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240016901A1 (en) * | 2020-05-28 | 2024-01-18 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating sars-cov-2 infection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011161644A1 (en) * | 2010-06-24 | 2011-12-29 | Panmed Ltd. | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2546658A (en) | 1949-07-23 | 1951-03-27 | Sterling Drug Inc | 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation |
US5314894A (en) | 1992-09-15 | 1994-05-24 | Sterling Winthrop Inc. | (S)-(+)-hydroxychloroquine |
US6849254B1 (en) | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
WO2001081359A1 (en) | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
US7410979B2 (en) | 2003-11-19 | 2008-08-12 | Rigel Pharmaceuticals, Inc. | Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
WO2006005610A1 (en) | 2004-07-14 | 2006-01-19 | Novartis Ag | Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv) |
WO2012176149A1 (en) | 2011-06-23 | 2012-12-27 | Panmed Ltd. | Treatment of hepatitis c virus |
-
2014
- 2014-02-04 WO PCT/IB2014/000760 patent/WO2014122537A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011161644A1 (en) * | 2010-06-24 | 2011-12-29 | Panmed Ltd. | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
Non-Patent Citations (6)
Title |
---|
CHANDRAMOHAN M ET AL: "Preliminary report of anti-hepatitis C virus activity of chloroquine and hydroxychloroquine in huh-5-2 cell line", INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, MEDKNOW PUBLICATIONS PVT LTD, IN, vol. 68, no. 4, February 2006 (2006-02-01), pages 538 - 540, XP002664360, ISSN: 0250-474X, DOI: 10.4103/0250-474X.27842 * |
DIENSTAG ET AL: "American Gastroenterological Association Technical Review on the Management of Hepatitis C", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 130, no. 1, January 2006 (2006-01-01), pages 231 - 264, XP005245699, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2005.11.010 * |
JESPER BROK ET AL: "Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials", THE AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 101, no. 4, April 2006 (2006-04-01), pages 842 - 847, XP055129030, ISSN: 0002-9270, DOI: 10.1111/j.1572-0241.2006.00505.x * |
MALIK ARSHAD H ET AL: "A pilot study of hydroxychloroquine in the treatment of chronic hepatitis C", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 116, no. 4, April 1999 (1999-04-01), pages A1242 - A1243, XP009154231, ISSN: 0016-5085 * |
TANABE Y ET AL: "998 Direct inhibition of intracellular hepatitis C virus replication by ribavirin and its synergistic action used in combination with interferon-alpha", HEPATOLOGY (AASLD ABSTRACTS), WILEY, USA, vol. 38, January 2003 (2003-01-01), pages 637, XP004624209, ISSN: 0270-9139, DOI: 10.1016/S0270-9139(03)81036-4 * |
THOMPSON A ET AL: "Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 50, no. 1, January 2009 (2009-01-01), pages 184 - 194, XP025769626, ISSN: 0168-8278, [retrieved on 20081104], DOI: 10.1016/J.JHEP.2008.10.011 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014122537A2 (en) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005054A (en) | Combination of two antivirals for treating hepatitis c. | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
WO2012027712A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
HRP20171898T1 (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
JP2016508134A5 (en) | ||
EA201201235A1 (en) | PHARMACEUTICAL AGENT COMBINATIONS AS HCV REPLICATION INHIBITORS | |
PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
JP2014530874A5 (en) | ||
MX2012011222A (en) | Compounds and pharmaceutical compositions for the treatment of viral infections. | |
EA201301158A1 (en) | ANTI-VIRUS COMPOUNDS | |
EP2583677A3 (en) | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. | |
MD20140058A2 (en) | Compositions and methods for treating hepatitis C virus | |
MX2016012799A (en) | Methods for treating hcv. | |
MX2014002171A (en) | Combination treatments for hepatitis c. | |
MX2011007195A (en) | Cyclosporine derivative for use in the treatment of hcv and hiv infection. | |
MX2013000242A (en) | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent. | |
MY194294A (en) | Novel viral replication inhibitors | |
JP2016513703A5 (en) | ||
WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
PH12016502039A1 (en) | Potent and selective inhibitors of hepatitis c virus | |
MX2018000240A (en) | Methods for treating hcv. | |
MX2016012722A (en) | Methods for treating hcv. | |
RU2015114566A (en) | HEPATITIS TREATMENT METHODS | |
WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14732935 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14732935 Country of ref document: EP Kind code of ref document: A2 |